Current experiences with a quality management system for non-clinical research and development in pharmaceutical industry

被引:0
|
作者
Barbara Pohl
Stephanie Simon
Peter-Jürgen Kramer
机构
[1] Merck KGaA,
[2] Merck Serono Research/TOX-GLP,undefined
[3] Non Clinical Development,undefined
[4] Institute of Toxicology,undefined
[5] Merck KGaA,undefined
[6] Merck Serono Research/Quality Assurance,undefined
来源
Accreditation and Quality Assurance | 2008年 / 13卷
关键词
MSR-QMS (Merck Serono Research-quality management system); Optimizing of processes in research; Validation; IT lifecycle;
D O I
暂无
中图分类号
学科分类号
摘要
Quality management is one of the most important issues in pharmaceutical research as it determines the validity and reliability of data, data and data evaluation being the central products of all research activities. In this business it is of outstanding importance to generate valid data for the assessment of drug development candidates to assure that the huge financial investment, which is based on such assessments, can be successful. Efficacy and safety of products are the final goals of such developments. Therefore, Merck/Merck Serono implemented an additional specifically developed quality management system that covers all areas and locations in Merck Serono Research that were not yet regulated by an existing regulatory quality management system, e.g. GLP (Good Laboratory Practice). The system is known under the name Merck Serono Research-Quality Management System (MSR-QMS). Thus, we describe the implementation process of MSR-QMS as a research specific quality management system in a global company. Furthermore, the implementation process in one specific research department will be highlighted. Using a practical example, the validation of an analytical instrument in a MSR-QMS-regulated research laboratory will be shown and compared to a validation process in a strictly GLP-regulated area. A summary of the experiences with the new quality system will complete this article and the advantages of high quality research results in industry will be discussed.
引用
收藏
页码:511 / 521
页数:10
相关论文
共 50 条
  • [31] Childhood victimisation and developmental expression of non-clinical delusional ideation and hallucinatory experiencesVictimisation and non-clinical Psychotic experiences
    Tineke Lataster
    Jim van Os
    Marjan Drukker
    Cécile Henquet
    Frans Feron
    Nicole Gunther
    Inez Myin-Germeys
    Social Psychiatry and Psychiatric Epidemiology, 2006, 41 : 423 - 428
  • [32] Use of a dossier management system in the pharmaceutical industry - Selection, implementation and experiences from use
    Kainz, A
    Harmsen, S
    PHARMAZEUTISCHE INDUSTRIE, 2003, 65 (5A): : 511 - 519
  • [33] A Compliance Management System for the Pharmaceutical Industry
    Fisher, Julie
    Aldea, Arantza
    Banares-Alcantara, Rene
    18TH EUROPEAN SYMPOSIUM ON COMPUTER AIDED PROCESS ENGINEERING, 2008, 25 : 949 - 954
  • [34] Clinical Research, the pharmaceutical industry and the biomedical research teaching
    Gamba, Gerardo
    GACETA MEDICA DE MEXICO, 2023, 159 (04): : 361 - 362
  • [35] Political Management, Research and Development, and Advertising Capital in the Pharmaceutical Industry: A Good Prognosis?
    Martin, Kelly D.
    Josephson, Brett W.
    Vadakkepatt, Gautham G.
    Johnson, Jean L.
    JOURNAL OF MARKETING, 2018, 82 (03) : 87 - 107
  • [36] CLINICAL RESEARCH IN EPILEPSY IS DOMINATED BY THE PHARMACEUTICAL INDUSTRY
    Morrow, J.
    Bergin, P.
    EPILEPSIA, 2009, 50 : 5 - 5
  • [37] Application Research of Pharmaceutical Industry Management System Based on ERP and CRM Integration
    Wan, Xiaoyan
    Xu, Guoqing
    ADVANCES IN ENGINEERING DESIGN AND OPTIMIZATION II, PTS 1 AND 2, 2012, 102-102 : 55 - +
  • [38] PHARMACEUTICAL-INDUSTRY CAREERS IN CLINICAL RESEARCH
    COHEN, I
    BENDER, J
    CILLA, D
    TEXTER, M
    MCCORMICK, L
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1990, 47 (11): : 2446 - 2446
  • [39] Pre-clinical research in the pharmaceutical industry
    Johnston, DS
    Kopf, GS
    JOURNAL OF ANDROLOGY, 2005, 26 (01): : 13 - 14
  • [40] Is the current non-clinical drug development safety paradigm effective for assessing cardiovascular liabilities?
    Roche, Brian
    Ross, John
    Obejero-Paz, Carlos A.
    Kramer, James
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2019, 99